Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist

Cardiology

Volumn 89, Issue SUPPL. 1, 1998, Pages 23-32

  Kobrin, Isaac ^a   Bieska, Gabriele ^a   Charlon, Vincent ^a   Lindberg, Elisabet ^a   Pordy, Robert ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Amlodipine; Anti anginal therapy; Anti ischemic therapy; Diltiazem SR; Mibefradil

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL; DILTIAZEM; MIBEFRADIL; NITRATE;

ANGINA PECTORIS; ANKLE EDEMA; ATRIOVENTRICULAR BLOCK; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; EXERCISE TEST; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SINUS BRADYCARDIA;

ADOLESCENT; ADULT; AMLODIPINE; ANGINA PECTORIS; BENZIMIDAZOLES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HUMANS; MALE; MIBEFRADIL; MIDDLE AGED; MYOCARDIAL ISCHEMIA; SAFETY; TETRAHYDRONAPHTHALENES;

EID: 0031890297     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047276     Document Type: Conference Paper

References (28)

1. 2+ channels by Ro 40-5967. Circ Res 1994;75:144-148.
2. Clozel J-P, Banken L, Osterrieder W: Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: Comparison with verapamil. J Cardiovasc Pharmacol 1989;14:713-721.
3. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990;4: 731-736.
4. Portegies M, Schmitt R, Kraaij C, et al: Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991; 18:746-751.
5. Bernink P, Prager G, Schelling A, Kobrin I: Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): A new generation of calcium antagonists? Hypertension 1996;27:426-432.
6. Schmitt R, Kleinbloesem C, Belz G, et al: Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992; 52:314-323.
7. Bakx A, van der Wall E, Braun S, Emanuelsson H, Bruschke A, Kobrin I: Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study. Am Heart J 1995;130:748-757.
8. Braun S, van der Wall E, Emanuelsson H, Kobrin I: Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: A multicenter placebo-controlled study. J Am Coll Cardiol 1996;27:317-322.
9. Tzivoni D, Kadr H, Braat S, Rutsch W, Ramires J, Kobrin I: Efficacy of mibefradil in comparison to amlodipine in suppressing exercise-induced and daily silent ischemia: Results of a multicenter, placebo-controlled trial. Circulation, in press.
10. Alpert J, Kobrin I, DeQuattro V, Friedman R, Shepherd A, Fenster P: Additional anti-anginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta-blocker for chronic stable angina pectoris. Am J Cardiol 1997;79:1025-1030.
11. Schneeweiss A, Kobrin I, Caspi A, et al: Adding the new calcium antagonist mibefradil to patients on chronic beta-blocker therapy results in improved anti-anginal and anti-ischemic efficacy. Am Heart J, in press.
12. Davies G, Kobrin I, Caspi A, et al: Long-term anti-anginal and anti-ischemic effects of mibefradil, the novel T-type calcium channel blocker: A multicenter, double-blind, placebo-controlled, randomized comparison with diltiazem SR. Am Heart J, in press.
13. Bursztyn M, Kadr H, Tilvis R, et al: Mibefradil, a novel calcium antagonist, in elderly hypertensives: Favorable hemodynamics and pharmacokinetics. Am Heart J, in press.
14. Oparil S, Kobrin I, Abernethy D, Levine B, Reif M, Shepherd A: Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens 1997;10:735-742.
15. Pepine C, Cohn P, Deedwania P, et al: Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: The Atenolol Silent Ischemia Study (ASIST). Circulation 1994;90:762-768.
16. Taylor S: The efficacy of amlodipine in myocardial ischemia. Am Heart J 1989;118:1123-1126.
17. Weiner D, Cutter S, Klein M: Efficacy and safety of sustained-release diltiazem in stable angina pectoris. Am J Cardiol 1986;57:6-9.
18. Frishman W: Current status of calcium channel blockers. Curr Probl Cardiol 1994;19:639-688.
19. Triggle D: Calcium antagonists; in Antonaccil M (ed): Cardiovascular Pharmacology. New York, Raven, 1990, pp 107-160.
20. Dyer A, Persky V, Stamler J, et al: Heart rate as a prognostic factor for coronary heart disease and mortality: Findings in three Chicago epidemiologic studies. Am J Epidemiol 1980;112: 736-749.
21. Gillum R, Makuc D, Feldman J: Pulse rate, coronary heart disease, and death: The NHANES I epidemiologic follow-up study. Am Heart J 1991;121:172-177.
22. Kannel W, Kannel C, Paffenbarger R, Cupples A: Heart rate and cardiovascular mortality: The Framingham Study. Am Heart J 1987;113: 1489-1494.
23. Palatini P, Julius S: Heart rate and the cardiovascular risk. J Hypertens 1997;15:3-17.
24. Perski A, Ollson G, Landou C, de Faire U, Theorell T, Hamsten A: Minimum heart rate and coronary atherosclerosis: Independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 1992; 123:609-616.
25. Thaulow E, Erikssen J: How important is heart rate? J Hypertens 1991;9:527-530.
26. Rosenquist M, Brembilla-Perrot B, Meinertz T, et al: The acute effects of intravenously administered mibefradil on the electrophysiologic characteristics of the human heart. Eur J Clin Pharmacol 1997;52:7-12.
27. Rousseau M, Hayashida W, van Eyll C, et al: Hemodynamic and cardiac effects of the selective T-type cacium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol 1996;28:972-979.
28. Levine T: The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil). Clin Cardiol 1997;20: 320-326.